Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases.


Journal

Microbiological research
ISSN: 1618-0623
Titre abrégé: Microbiol Res
Pays: Germany
ID NLM: 9437794

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 18 07 2018
revised: 09 09 2018
accepted: 28 09 2018
entrez: 21 11 2018
pubmed: 21 11 2018
medline: 12 1 2019
Statut: ppublish

Résumé

Helicobacter pylori (H. pylori) is a bacterial pathogen that resides in more than half of the human population and has co-evolved with humans for more than 58,000 years. This bacterium is orally transmitted during childhood and is a key cause of chronic gastritis, peptic ulcers and two malignant cancers including MALT (mucosa-associated lymphoid tissue) lymphoma and adenocarcinoma. Despite the strong innate and adaptive immune responses, H. pylori has a long-term survival in the gastric mucosa. In addition to the virulence factors, survival of H. pylori is strongly influenced by the ability of bacteria to escape, disrupt and manipulate the host immune system. This bacterium can escape from recognition by innate immune receptors via altering its surface molecules. Moreover, H. pylori subverts adaptive immune response by modulation of effector T cell. In this review, we discuss the immune-pathogenicity of H. pylori by focusing on its ability to manipulate the innate and acquired immune responses to increase its survival in the gastric mucosa, leading up to gastrointestinal disorders. We also highlight the mechanisms that resulted to the persistence of H. pylori in gastric mucosa.

Identifiants

pubmed: 30454658
pii: S0944-5013(18)30835-8
doi: 10.1016/j.micres.2018.09.011
pii:
doi:

Substances chimiques

Virulence Factors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-57

Informations de copyright

Copyright © 2018 Elsevier GmbH. All rights reserved.

Auteurs

Ahmad Karkhah (A)

Student Research Committee, Babol University of Medical Sciences, Babol, Iran; Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Soheil Ebrahimpour (S)

Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Maryam Rostamtabar (M)

Student Research Committee, Babol University of Medical Sciences, Babol, Iran.

Veerendra Koppolu (V)

Scientist Biopharmaceutical Development Medimmune Gaithersburg, MD, 20878 USA.

Sorena Darvish (S)

Student Research Committee, Babol University of Medical Sciences, Babol, Iran.

Veneela Krishna Rekha Vasigala (VKR)

Rangaraya Medical College, NTR University of Health Sciences, Kakinada, India.

Majid Validi (M)

Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Hamid Reza Nouri (HR)

Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Immunoregulation Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. Electronic address: nourihr851@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH